FFAR2 and neoplasm: The combination therapy strategy of FFAR2 pharmaceutical inhibition with anti-PD-1 antibody demonstrated superior antitumor effectiveness to anti-PD-1 antibody therapy alone in LLC subcutaneous mouse tumor model.